Strategies for discovering novel hepatocellular carcinoma biomarkers

doi:10.4254/wjh.v17.i2.101201

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=0

Feb 27, 2025 (publication date) through Feb 20, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Feb 27, 2025; 17(2): 101201
Published online Feb 27, 2025. doi: 10.4254/wjh.v17.i2.101201

Strategies for discovering novel hepatocellular carcinoma biomarkers

Shi-Tao Wu, Li Zhu, Xiao-Ling Feng, Hao-Yu Wang, Fang Li

Shi-Tao Wu, Hao-Yu Wang, Department of Hepatopancreatobiliary Surgery, Chongqing General Hospital, Chongqing 401147, China

Li Zhu, Xiao-Ling Feng, Fang Li, Department of General Surgery, Chongqing General Hospital, Chongqing 401147, China

Author contributions: Wu ST conceptualized the review, conducted the literature search, and drafted the initial manuscript; Zhu L contributed to the critical analysis of the literature and provided significant revisions to the manuscript; Feng XL assisted in the data interpretation and helped in organizing the structure of the review; Wang HY contributed to the sections on emerging technologies and future directions and provided expert input on the clinical implications. Li F as the corresponding author, oversaw the entire project, coordinated contributions from all authors, and finalized the manuscript for submission. All authors reviewed and approved the final version of the manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Fang Li, MD, PhD, Professor, Department of General Surgery, Chongqing General Hospital, No. 118 Xingguang Avenue, Liangjiang New District, Chongqing 401147, China. leef123456@163.com

Received: September 9, 2024
Revised: November 13, 2024
Accepted: December 23, 2024
Published online: February 27, 2025
Processing time: 165 Days and 23.3 Hours

Core Tip

Core Tip: This review provides a comprehensive analysis of current and emerging biomarkers for hepatocellular carcinoma, emphasizing the significance of multi-omics approaches in enhancing diagnostic accuracy and treatment strategies. It highlights the challenges in biomarker discovery, including pre-analytical, analytical, and post-analytical factors, and underscores the need for large-scale validation and cross-disciplinary collaboration. The insights presented aim to advance early detection, improve patient outcomes, and pave the way for personalized treatment approaches in liver cancer management.